image
Healthcare - Medical - Devices - NASDAQ - US
$ 5.875
0 %
$ 370 M
Market Cap
-6.79
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TMCI stock under the worst case scenario is HIDDEN Compared to the current market price of 5.88 USD, Treace Medical Concepts, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TMCI stock under the base case scenario is HIDDEN Compared to the current market price of 5.88 USD, Treace Medical Concepts, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TMCI stock under the best case scenario is HIDDEN Compared to the current market price of 5.88 USD, Treace Medical Concepts, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TMCI

image
$11.0$11.0$10.5$10.5$10.0$10.0$9.5$9.5$9.0$9.0$8.5$8.5$8.0$8.0$7.5$7.5$7.0$7.0$6.5$6.5$6.0$6.0$5.5$5.515 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
209 M REVENUE
11.89%
-55.7 M OPERATING INCOME
-8.28%
-55.7 M NET INCOME
-12.55%
-37.2 M OPERATING CASH FLOW
-7.50%
35.4 M INVESTING CASH FLOW
143.51%
160 K FINANCING CASH FLOW
-99.85%
52.6 M REVENUE
-23.49%
-15.6 M OPERATING INCOME
-7538.24%
-15.9 M NET INCOME
-3078.04%
4.2 M OPERATING CASH FLOW
199.79%
-1.89 M INVESTING CASH FLOW
-55.36%
-282 K FINANCING CASH FLOW
-1084.62%
Balance Sheet Treace Medical Concepts, Inc.
image
Current Assets 161 M
Cash & Short-Term Investments 75.7 M
Receivables 40.8 M
Other Current Assets 44.9 M
Non-Current Assets 55.7 M
Long-Term Investments 0
PP&E 34.4 M
Other Non-Current Assets 21.3 M
34.86 %18.80 %20.69 %15.84 %9.81 %Total Assets$217.1m
Current Liabilities 34.9 M
Accounts Payable 10.5 M
Short-Term Debt 413 K
Other Current Liabilities 24 M
Non-Current Liabilities 69.3 M
Long-Term Debt 69.2 M
Other Non-Current Liabilities 37 K
10.10 %23.02 %66.45 %Total Liabilities$104.2m
EFFICIENCY
Earnings Waterfall Treace Medical Concepts, Inc.
image
Revenue 209 M
Cost Of Revenue 41.1 M
Gross Profit 168 M
Operating Expenses 224 M
Operating Income -55.7 M
Other Expenses 55 K
Net Income -55.7 M
250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)209m(41m)168m(224m)(56m)(55k)(56m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
80.37% GROSS MARGIN
80.37%
-26.60% OPERATING MARGIN
-26.60%
-26.63% NET MARGIN
-26.63%
-49.38% ROE
-49.38%
-25.68% ROA
-25.68%
-30.50% ROIC
-30.50%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Treace Medical Concepts, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)(50m)(50m)202020202021202120222022202320232024202420252025
Net Income -55.7 M
Depreciation & Amortization 8.42 M
Capital Expenditures -11.6 M
Stock-Based Compensation 0
Change in Working Capital -25.4 M
Others 1.73 M
Free Cash Flow -48.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Treace Medical Concepts, Inc.
image
Wall Street analysts predict an average 1-year price target for TMCI of $13.3 , with forecasts ranging from a low of $9.5 to a high of $16 .
TMCI Lowest Price Target Wall Street Target
9.5 USD 61.70%
TMCI Average Price Target Wall Street Target
13.3 USD 126.95%
TMCI Highest Price Target Wall Street Target
16 USD 172.34%
Price
Max Price Target
Min Price Target
Average Price Target
1616141412121010886644Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Treace Medical Concepts, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
398 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
524 K USD 1
3-6 MONTHS
266 K USD 1
6-9 MONTHS
1.01 M USD 2
9-12 MONTHS
7. News
TMCI Investors Have Opportunity to Join Treace Medical Concepts, Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES , June 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ: TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. prnewswire.com - 1 week ago
Levi & Korsinsky Notifies Treace Medical Concepts, Inc. (TMCI) Shareholders of Class Action Lawsuit and June 10, 2025 Deadline NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your Treace Medical Concepts, Inc. (NASDAQ:TMCI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/treace-medical-concepts-inc-lawsuit-submission-form-2?prid=151894&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
TMCI INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Treace Medical Concepts, Inc. to Contact the Firm Today! NEW YORK CITY, NY / ACCESS Newswire / June 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Treace Medical Concepts, Inc. ("Treace Medical" or "the Company") (NASDAQ:TMCI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Treace Medical securities between May 8, 2023 and May 7, 2024, both dates inclusive (the "Class Period"). accessnewswire.com - 1 week ago
Lost Money on Treace Medical Concepts, Inc.(TMCI)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky NEW YORK , June 6, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc." or the "Company") (NASDAQ: TMCI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Treace Medical Concepts, Inc. investors who were adversely affected by alleged securities fraud between May 8, 2023 and May 7, 2024. prnewswire.com - 1 week ago
Investors in Treace Medical Concepts, Inc. (TMCI): Protect Your Rights - Contact Levi & Korsinsky Before June 10, 2025 NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Treace Medical Concepts, Inc. (NASDAQ:TMCI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/treace-medical-concepts-inc-lawsuit-submission-form-2?prid=151820&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
Lost Money on Treace Medical Concepts, Inc. (TMCI)? Contact Levi & Korsinsky to Join Class Action Before June 10, 2025 NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Treace Medical Concepts, Inc. (NASDAQ:TMCI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/treace-medical-concepts-inc-lawsuit-submission-form-2?prid=151812&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
TMCI FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action – TMCI NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline. globenewswire.com - 1 week ago
Contact Levi & Korsinsky by June 10, 2025 to Join Class Action Against Treace Medical Concepts, Inc. (TMCI) NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Treace Medical Concepts, Inc. (NASDAQ:TMCI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/treace-medical-concepts-inc-lawsuit-submission-form-2?prid=151803&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
Levi & Korsinsky Urges Treace Medical Concepts, Inc. (TMCI) Shareholders to Act Before Lead Plaintiff Deadline June 10, 2025 NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Treace Medical Concepts, Inc. (NASDAQ:TMCI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/treace-medical-concepts-inc-lawsuit-submission-form-2?prid=151802&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 10, 2025 in Treace Medical Concepts, Inc. Lawsuit – TMCI NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc." or the "Company") (NASDAQ: TMCI) of a class action securities lawsuit. globenewswire.com - 1 week ago
Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology PONTE VEDRA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ®  and Adductoplasty ®  procedures, today announced that it filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, “Zimmer”) (NYSE: ZBH), alleging infringement of 4 patents related to Treace's innovative Lapiplasty® 3D Bunion Correction® technologies. The suit was filed in the United States District Court for the District of Delaware, and seeks injunctive relief and damages. globenewswire.com - 1 week ago
Securities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) Investors - Contact Levi & Korsinsky Before June 10, 2025 NEW YORK, NY / ACCESS Newswire / June 5, 2025 / If you suffered a loss on your Treace Medical Concepts, Inc. (NASDAQ:TMCI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/treace-medical-concepts-inc-lawsuit-submission-form-2?prid=151775&wire=1&utm_campaign=2 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
8. Profile Summary

Treace Medical Concepts, Inc. TMCI

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 370 M
Dividend Yield 0.00%
Description Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
Contact 203 Fort Wade Road, Ponte Vedra, FL, 32081 https://www.treace.com
IPO Date April 23, 2021
Employees 477
Officers Dr. Sean F. Scanlan Ph.D. Chief Innovation Officer Mr. Aaron J. Berutti Senior Vice President of Sales Mr. Taylor Erickson Chief Information & Cybersecurity Officer Mr. Daniel E. Owens Chief Human Resources Officer Mr. Scot M. Elder J.D. Chief Legal & Compliance Officer and Corporate Secretary Mr. Terry W. Lubben Chief Operations & Supply Chain Officer Ms. Shana Zink Senior Vice President of Clinical Affairs & Reimbursement Mr. John T. Treace Chief Executive Officer, Founder & Director Mr. Gaetano M. Guglielmino Chief Commercial Officer Mr. Mark L. Hair CPA Chief Financial Officer